25 g x 5 8 syringe

Manufactured by BD

The 25 G x 5/8" syringe is a medical device designed for the administration of various injectable solutions. It features a 25-gauge needle with a length of 5/8 inches, suitable for a variety of injection techniques. The syringe is constructed to provide a controlled and accurate delivery of the desired fluid volume.

Automatically generated - may contain errors

Lab products found in correlation

Penicillin streptomycin, by Thermo Fisher Scientific (1 mentions) Glutamax, by Thermo Fisher Scientific (1 mentions) Ack lysing buffer, by Lonza (1 mentions) Nu j mice, by Jackson ImmunoResearch (1 mentions)

Spelling variants of this product

25-G syringe (2 citations)

2 protocols using 25 g x 5 8 syringe

Murine Immune Response Profiling

Check if the same lab product or an alternative is used in the 5 most similar protocols

Sample collection: Seven to sixty days post-immunization, mice were anesthetized with isoflurane and blood was collected from the orbital sinus using capillary tubes without anticoagulant for sera separation. Inguinal and popliteal lymph nodes (LNs), spleens and both tibias and femurs were harvested and placed in cold complete Dulbecco’s Modified Eagle’s Medium [(DMEM, Corning, T10014CV) containing 10% heat inactivated Fetal Bovine Serum (FBS, Corning, 35-015), 1% Glutamax (Gibco, 35050-061) and 1% Penicillin/Streptomycin (Gibco, 5070063)]. All organs were kept on ice and immediately processed after collection.
LNs and spleen processing: Organs were homogenized with a syringe plunger and filtered through a 40 μm cell strainer on ice. Red blood cells (RBCs) of spleens were lysed using ACK lysing buffer (Lonza, 10-548E) for 5-8 minutes on ice and the reaction was stopped with cold PBS.
Bone Marrow (BM) processing: BM was flushed from both femurs and tibias from each mouse using a 1 mL 25 G x 5/8” syringe (BD Biosciences, 30962). RBCs were lysed as described above.
Cells from all tissues were resuspended in ice cold complete DMEM and immediately used for counting, culture, or staining.
Serum processing. Following collection, blood was centrifuged at 14,000 x g (maximum speed) for 30 minutes, 4°C. Serum was recovered and stored at -20°C for neutralization assays and ELISAs.

Lederer K., Castaño D., Gómez Atria D., Oguin TH I.I.I., Wang S., Manzoni T.B., Muramatsu H., Hogan M.J., Amanat F., Cherubin P., Lundgreen K.A., Tam Y.K., Fan S.H., Eisenlohr L.C., Maillard I., Weissman D., Bates P., Krammer F., Sempowski G.D., Pardi N, & Locci M. (2020). SARS-CoV-2 mRNA Vaccines Foster Potent Antigen-Specific Germinal Center Responses Associated with Neutralizing Antibody Generation. Immunity, 53(6), 1281-1295.e5.

+ Open protocol

+ Expand

Xenograft Tumor Formation Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols

To assay tumor formation, cells were harvested and resuspended in cold PBS. For A2780 xenograft experiments, 3 million cells were injected in each flank of NU/J mice (Jackson Laboratory, cat. no. 002019). For A2058 xenograft experiments, 2 million cells were injected in each flank in NU/J mice. For HCT116 xenograft experiments, 4 million cells were injected in J:NU mice (Jackson Laboratory, cat. no. 007850). For MCF10A cells expressing HRAS^G12V, 10 million cells were injected in each flank in NU/J mice. For AGS xenograft experiments, the following conditions were tried: 5 million cells resuspended in PBS in each flank of NU/J mice (Jackson Laboratory, cat. no. 002019); 4 million cells resuspended in PBS in each flank of NGS mice (Jackson Laboratory, cat. no. 005557); and 15 million cells resuspended in a 1:1 PBS:Matrigel mixture in each flank of J:NU mice (Jackson Laboratory, cat. no. 007850). Cells were subcutaneously injected using a 1 mL 25G x 5/8 syringe (BD, cat. no. 309626). Mice were visually monitored for tumor formation routinely following injection. Once a tumor was visible, it was measured every three days by calipers. Tumor volume was calculated using the formula V = ½ (longer axis)(shorter axis). All mouse protocols were approved by the CSHL and Yale Institutional Animal Care and Use Committees.

Girish V., Lakhani A.A., Scaduto C.M., Thompson S.L., Brown L.M., Hagenson R.A., Sausville E.L., Mendelson B.E., Lukow D.A., Yuan M.L., Kandikuppa P.K., Stevens E.C., Lee S.N., Salovska B., Li W., Smith J.C., Taylor A.M., Martienssen R.A., Liu Y., Sun R, & Sheltzer J.M. (2023). Oncogene-like addiction to aneuploidy in human cancers. bioRxiv.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!